Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Recruiting 3Completed 2Withdrawn 1Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Pancreatic Neoplasms 3Carcinoma 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Prostatic Neoplasms 1Primary Myelofibrosis 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Fibrolamellar hepatocellular carcinoma 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Biliary Tract Neoplasms 1Adenocarcinoma 1

Interventions

Gemcitabine 54130-nm albumin-bound paclitaxel 29Magnetic Resonance Spectroscopy 21Taxes 18Fluorouracil 18Specimen Handling 17Oxaliplatin 17Leucovorin 17Drug Therapy 17Albumin-Bound Paclitaxel 17Irinotecan 14pembrolizumab 13Cyclophosphamide 11Blood Specimen Collection 11Biopsy 11fludarabine 10Radiosurgery 9irinotecan sucrosofate 8folfirinox 6Magnetic Resonance Imaging 6Cetuximab 6Bevacizumab 6dehydroftorafur 5Surveys and Questionnaires 5Nivolumab 5Endoscopic Ultrasound-Guided Fine Needle Aspiration 5sintilimab 4olaparib 4balstilimab 4Surgical Procedures, Operative 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Pancreatic Neoplasms × poly ICLC × Clear all
NCT06411691 2025-12-18

KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Recruiting
54 enrolled
Gastrointestinal

Colonic Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05013216 2025-12-03

Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Recruiting
37 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06782932 2025-12-03

Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Recruiting
38 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡